STXI - ETF AI Analysis
Top Page
(undefined)
Rating:69Neutral
Price Target:―
Positive Factors
Broad Country Diversification
The fund spreads its investments across many developed markets like Japan, the UK, the U.S., and several European and Asia-Pacific countries, reducing reliance on any single economy.
Balanced Sector Mix
Holdings are spread across financials, industrials, technology, health care, and other sectors, helping to cushion the impact if one industry struggles.
Improving Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Negative Factors
Heavy Tilt Toward Financials
A large share of the portfolio is in financial stocks, which can make the fund more sensitive to interest rate changes and banking sector stress.
Mixed Results Among Top Holdings
While some leading positions like ASML and Siemens have performed strongly, others such as SAP, Nestlé, AstraZeneca, and Royal Bank of Canada have been weaker, creating uneven contribution to returns.
Moderate Expense Ratio
The fund’s fee is not especially high but is also not among the cheapest international ETFs, slightly reducing net returns over time.
STXI vs. SPDR S&P 500 ETF (SPY)
AUMN/A
RegionN/A
Expense RatioN/A
BetaN/A
IssuerN/A
Inception DateN/A
Dividend YieldN/A
Asset ClassN/A
Index TrackedN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst CoveringN/A
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
STXI Summary
The Strive International Developed Markets ETF (STXI) tracks the Bloomberg Developed Markets ex US Large & Mid Cap Index, giving you broad exposure to stocks in developed countries outside the United States, such as Japan, the UK, and Europe. It owns many well-known companies like Toyota, Nestlé, and ASML, and spreads your money across sectors including financials, industrials, and technology. Someone might invest in STXI to diversify beyond the U.S. market and tap into growth in other major economies. A key risk is that international stock prices can be volatile and move up or down with global markets and currency swings.
How much will it cost me?The Strive International Developed Markets ETF (STXI) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is passively managed but focuses on a broad international market niche, which can involve additional complexities compared to U.S.-focused funds.
What would affect this ETF?The Strive International Developed Markets ETF (STXI) could benefit from economic growth in developed markets outside the U.S., particularly if sectors like financials, technology, and healthcare continue to innovate and expand. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance, especially for top holdings like ASML, Nestlé, and HSBC that are sensitive to global economic conditions.
STXI Top 10 Holdings
STXI leans heavily on big non-U.S. financials and global blue chips, and lately that mix has been a bit of a tug-of-war. Shell is one of the clear engines, with energy strength giving the fund a welcome push. ASML has been more mixed, still a long-term star for the semiconductor theme but recently catching its breath. On the defensive side, giants like Novartis and AstraZeneca are steady but not sprinting, while banks such as HSBC and Royal Bank of Canada have been lagging, acting like a mild anchor on this broadly diversified developed-markets ex-U.S. portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.06% | $657.95K | €437.91B | 80.67% | 76 Outperform | |
| Novartis AG | 1.71% | $368.63K | CHF217.50B | 20.81% | 80 Outperform | |
| AstraZeneca | 1.63% | $351.08K | $294.26B | 25.28% | 80 Outperform | |
| HSBC Holdings | 1.61% | $346.56K | £206.10B | 35.53% | 80 Outperform | |
| Roche Holding AG | 1.59% | $342.07K | $312.77B | 14.82% | 73 Outperform | |
| Shell (UK) | 1.52% | $327.25K | £195.69B | 24.51% | 73 Outperform | |
| Nestlé SA | 1.44% | $311.11K | CHF193.16B | -5.58% | 71 Outperform | |
| Royal Bank Of Canada | 1.27% | $273.12K | $220.90B | 41.08% | 75 Outperform | |
| Toyota Motor | 1.26% | $272.02K | ¥44.42T | 21.37% | 80 Outperform | |
| Commonwealth Bank of Australia | 1.19% | $256.65K | AU$290.27B | 15.42% | 64 Neutral |
STXI Technical Analysis
Negative
―
Price Trends
32.52
Negative
31.58
Negative
30.20
Positive
Market Momentum
-0.57
Positive
37.25
Neutral
41.95
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXI, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 31.74, equal to the 50-day MA of 32.52, and equal to the 200-day MA of 30.20, indicating a neutral trend. The MACD of -0.57 indicates Positive momentum. The RSI at 37.25 is Neutral, neither overbought nor oversold. The STOCH value of 41.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for STXI.
STXI Peer Comparison
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents